Stoke Therapeutics (STOK) shares have climbed after the company shared promising clinical results with Biogen. The results showed reduced seizures and improved cognition for Dravet syndrome patients over three years. Quarterly earnings also topped Wall Street’s expectations.

After hitting a 52-week high, Stoke Therapeutics’ share price has benefited from upbeat clinical results and quarterly earnings surprises. Momentum has picked up as investors grow more optimistic about the pipeline. The one-year total shareholder return is also now in positive territory.

If updates like these have you watching the healthcare sector, this is a prime time to see the full picture and discover See the full list for free.

With shares rallying to new highs and investor optimism close to a peak, the real question is whether Stoke Therapeutics offers further upside from here or if the recent gains mean future growth is already fully reflected in the price.

Price-to-Earnings of 25.9x: Is it justified?

Stoke Therapeutics trades at a price-to-earnings (P/E) ratio of 25.9x, which is higher than many of its sector peers. The current share price reflects this multiple and suggests the market may be pricing in optimistic scenarios or rewarding recent profitability.

The price-to-earnings ratio measures how much investors are willing to pay for each dollar of reported earnings. For a company like Stoke Therapeutics, operating in biotech, this is critical as investors assess whether recent profit milestones are sustainable or a one-off.

Compared to the US biotech industry average P/E of 17.2x, STOK’s ratio appears more expensive. Notably, the estimated “fair” P/E for Stoke is just 11.9x, which is a level the market could gravitate towards if growth or profitability expectations soften.

Result: Price-to-Earnings of 25.9x (OVERVALUED)

However, slowing annual revenue and net income growth suggest challenges remain. This could quickly dampen sentiment if momentum falters or results disappoint.

Another View: What Does the SWS DCF Model Suggest?

Taking a different angle, our DCF model estimates Stoke Therapeutics’ fair value at just $3.64, compared to its current price of $24.82. This suggests the shares may be significantly overvalued. Are investors betting too much on future breakthroughs, or is the market seeing something the model misses?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Stoke Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Stoke Therapeutics Narrative

If you think there’s another side to this story or would rather dive into the details yourself, you can craft your own take in just a few minutes. Do it your way

A great starting point for your Stoke Therapeutics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Smart investors like you do not settle for just one great pick. Seize your edge now with fresh and powerful opportunities tailor-made for ambitious portfolios.

• Accelerate your growth by targeting unbeatable income streams with these 19 dividend stocks with yields > 3%. Focus on stocks that offer yields above 3% and robust financial health.
• Spot the most promising breakthroughs by tapping into these 31 healthcare AI stocks and find out which companies are transforming healthcare with artificial intelligence.
• Uncover tomorrow’s leaders at today’s prices through these 909 undervalued stocks based on cash flows. Get ahead of the crowd by focusing on stocks priced below their cash flow value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.